Stop GLP‑1, regain ~10 kg
- A BMJ meta-analysis of 37 studies found adults stopping weight-loss drugs regained weight quickly, with semaglutide and tirzepatide users returning near baseline fastest. - Across 9,341 participants, average regain was 0.4 kilograms a month; newer incretin drugs were linked to roughly 0.8 kilograms monthly after stopping. - Cardiometabolic gains also faded, with markers projected back to baseline in 1.4 years. (bmj.com)
Glucagon-like peptide-1 drugs help people lose weight by dialing down appetite, but a new BMJ review found much of that weight returns after treatment stops. (bmj.com) The review, published January 7, 2026, pooled 37 studies covering 9,341 adults who used 13 weight-management medicines, including semaglutide and tirzepatide. (bmj.com) Across all drugs, people regained weight at an average rate of 0.4 kilograms a month after stopping treatment. For semaglutide and tirzepatide, the pace was about 0.8 kilograms a month. (bmj.com) (tctmd.com) The BMJ authors projected that people would return to baseline weight about 1.7 years after stopping any weight-loss medication. For incretin-based drugs, including semaglutide and tirzepatide, the return was closer to 1.6 years. (bmj.com) (tctmd.com) These medicines mimic gut hormones that signal fullness, so patients often eat less while taking them. When the drug is withdrawn, appetite and weight-regulating biology can rebound. (bmj.com) (thelancet.com) The review also found that cardiometabolic improvements did not hold steady after treatment ended. Blood sugar, blood pressure, and cholesterol measures were projected to drift back to baseline within 1.4 years. (bmj.com) (tctmd.com) Stopping treatment is common in practice, not just in trials. A JAMA Network Open cohort study of more than 125,000 U.S. adults with overweight or obesity tracked discontinuation and later reinitiation of glucagon-like peptide-1 receptor agonists. (jamanetwork.com) A separate Penn Medicine study, published April 28, 2026 in JCI Insight, found in mice that repeated stop-and-start semaglutide use led to weaker weight loss than continuous treatment. After 62 days of steady dosing, the intermittent group still weighed 20% more than the always-on group. (pennmedicine.org) That Penn study was preclinical, so it does not prove the same effect in people. But it adds to the clinical picture that obesity treatment often behaves more like long-term blood-pressure therapy than a short course of antibiotics. (pennmedicine.org) (bmj.com) Patients who stop because of cost, insurance limits, or side effects may still keep some benefit if they switch to other long-term strategies, including nutrition counseling, exercise, or other medicines. The BMJ review’s central finding is narrower: without ongoing treatment, regained weight tends to arrive quickly. (tctmd.com) (bmj.com)
